Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Recce Ltd
RCERecce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis rapid infusion; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. Recce Pharmaceuticals has strategic partnership with Murdoch Children's Research Institute for development of the Neisseria gonorrhoeae, Mycobacterium abscessus, and Escherichia coli clinical trials. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia. Address: Salesforce Tower, Sydney, NSW, Australia, 2000
Analytics
Precio Objetivo de WallStreet
3.94 AUDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave RCE
Análisis de dividendos RCE
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - ожидаемая <5 дивидендная доходность по себестоимости за 10 лет MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout RCE
Valoración de la acción RCE
Finanzas RCE
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |